With consumer health behind it, GSK taps AstraZeneca vet Julie Brown as CFO for R&D-focused future

Amber Tong

Four years ago, Emma Walmsley recruited Iain Mackay from the banking world to become GSK’s CFO, spotlighting his “track record of driving cost, cash …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With consumer health behind it, GSK taps AstraZeneca vet Julie Brown as CFO for R&D-focused future

Amber Tong

Sign up to read this article for free.

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CMS explains what went into its first round of drug price negotiations

With con­sumer health be­hind it, GSK taps As­traZeneca vet Julie Brown as CFO for R&D-fo­cused fu­ture

Amber Tong

Sign up to read this article for free.

more like this

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

With consumer health behind it, GSK taps AstraZeneca vet Julie Brown as CFO for R&D-focused future

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CMS explains what went into its first round of drug price negotiations